Can one nutraceutical ingredient address nearly all inflammatory diseases? A significant and fast-growing body of published research on a unique botanical agent is suggesting exactly that, reports Anat Stern, CEO, ecoNugenics
Based on independent data, treatment indications for a specific form of modified citrus pectin (MCP) continue to expand, propelling this natural ingredient to the apex of today’s nutraceutical pharmacopeia.
With more than 50 published studies and new findings constantly emerging in the literature, this form of MCP continues to surpass expectations by demonstrating efficacy against every proinflammatory condition it has been tested against.
From organ fibrosis and metastatic cancer to neurological damage, its singular ability to halt and reverse fundamental pathogenic processes have earned this MCP considerable recognition in areas of medical research wherein safe, effective interventions — holistic or conventional — are often few and far between.
Moving beyond cancer and cardiovascular disease
During the last several decades, 16 published clinical and preclinical studies have established this MCP as a leading anticancer adjunct, active via multiple antitumorigenic mechanisms. The most recent published clinical study (Effect of Pectasol-C Modified Citrus Pectin (P-MCP) Treatment (tx) on PSA Dynamics in Non-Metastatic Biochemically Relapsed Prostate Cancer (BRPC) Patients (pts): Results of a Prospective Phase II Study) on this MCP is now completing its final arm, with additional results further substantiating its proven ability at 14.5 g/day to slow PSA doubling time and halt prostate cancer progression.1
With the capacity to promote apoptosis, block angiogenesis, slow metastasis, enhance oncology treatments and expose cancer to the immune system — among other benefits — this MCP remains a cornerstone of integrative cancer protocols.2,3
In addition to cancer, this form of MCP is also being studied intensively in cardiovascular disease, with results demonstrating its unique protective benefits. The most recent paper published in Scientific Reports in July 2019, demonstrates that this MCP reduces myocardial injury after ischaemic reperfusion.4 To date, this is now the fifteenth independent publication highlighting the critical role of this MCP in managing cardiovascular health.
In recent years, however, research groups worldwide have steadily expanded the disease indications for this ingredient beyond cancer and cardiovascular disease. Renowned institutes including Harvard University, Meir Medical Center and others are increasingly interested in studying this specific form of MCP against organ fibrosis, neurodegeneration, GI infection and numerous other conditions.
Concurrently, health professionals using this MCP across complex patient populations continue to observe first-hand the broad-spectrum benefits of this natural ingredient — magnifying the clinical relevance of what’s consistently reported in the published literature.
The most researched galectin-3 blocker
The wide-ranging success of this MCP against both acute and chronic inflammatory conditions, is largely derived from its unique relationship with the causative biomarker molecule, galectin-3 (Gal-3). Thousands of published studies, including large-scale cohort data, identify Gal-3 as an upstream driver of inflammatory, fibrotic and oncogenic diseases.5
Wait, there’s more: